首页> 外文期刊>Expert opinion on drug delivery >Progress and limitations of oral peptide delivery as a potentially transformative therapy
【24h】

Progress and limitations of oral peptide delivery as a potentially transformative therapy

机译:口服肽递送作为一种潜在的变革性疗法的进展和局限性

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Introduction Numerous formulation technologies have been developed to overcome challenges of oral peptide delivery. Understanding the advantages and limitations of each technology is important for the development of new delivery systems to enable oral delivery of peptides designed for parenteral administration. Areas covered This review summarizes key learnings from the use of permeation enhancers (PEs) for oral peptide delivery associated with solid dosage form optimization to maximize the PE effect. Furthermore, we will highlight the most recent emerging delivery strategies to improve oral peptide bioavailability such as nanoparticles, self-emulsifying drug delivery systems, gut shuttles, and ingestible devices. In addition, advantages and limitations of these technologies will be compared with the permeation enhancer technology. Expert opinion Despite the success of permeation enhancer technology in the FDA-approved oral peptide products, oral peptide delivery is still facing the immense challenge of low-to-single digit oral bioavailability. Optimization of drug product attributes such as dissolution kinetics is critical to improve permeation enhancer efficacy. The next frontiers to substantially increase oral bioavailability and transform injectable peptides to oral deliverables may be ingestible devices and ligand-mediated transport (gut shuttles). However, clinical studies are necessary to inform the safety and efficacy of these emerging technologies.
机译:引言 已经开发了许多配方技术来克服口服肽递送的挑战。了解每种技术的优势和局限性对于开发新的递送系统非常重要,该系统能够口服递送设计用于肠胃外给药的肽。涵盖的领域 本综述总结了使用渗透增强剂(PEs)进行口服肽递送的关键经验教训,这些经验与固体剂型优化有关,以最大限度地提高PE效果。此外,我们将重点介绍提高口服肽生物利用度的最新新兴递送策略,例如纳米颗粒、自乳化药物递送系统、肠道穿梭车和可摄入设备。此外,还将比较这些技术的优点和局限性,以增强渗透剂技术。专家意见 尽管渗透增强剂技术在FDA批准的口服肽产品中取得了成功,但口服肽递送仍面临着口服生物利用度低至个位数的巨大挑战。优化溶出动力学等药品属性对于提高渗透增强剂功效至关重要。大幅提高口服生物利用度并将可注射肽转化为口服可递送物的下一个前沿领域可能是可摄入装置和配体介导的运输(肠道穿梭)。然而,有必要进行临床研究,以告知这些新兴技术的安全性和有效性。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号